No Data
No Data
Aytu BioPharma Second Quarter 2024 Earnings: Beats Expectations
Earnings Call: Aytu BioPharma Achieves First Positive Operating Income
Earnings Call Summary | Aytu BioPharma(AYTU.US) Q2 2024 Earnings Conference
The following is a summary of the Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript:Financial Performance:Aytu BioPharma achieved $5.1 million in adjusted EBITDA, up from the previous year'
Aytu BioPharma Q2 2024 GAAP EPS $(0.04) Beats $(0.25) Estimate, Sales $22.93M Beat $21.75M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.25) by 84 percent. The company reported quarterly sales of $22.93 million
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, Vs. Street Est of $21.75M
04:07 PM EST, 02/14/2024 (MT Newswires) -- Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted E
No Data
heng heng888 : fda approve but why red. should be green..
71707398OP : hedgies playing games
TraderGuy : Got great news and has been tanking ever since. This is silly